| Sažetak | Lijekovi iz skupine statina putem inhibicije enzima HMG-CoA-reduktaze smanjuju razinu kolesterola u krvi. Kroz godine njihove široke primjene otkriveni su dodatni pleiotropni učinci statina. Pokazalo se da statini posjeduju i antiupalna, antioksidativna, antiagregacijska i antiproliferacijska svojstva. Glavni cilj ovog istraživanja bio je utvrditi utjecaj navedenih svojstava na ishod i tijek pneumonije.
U provedenoj studiji retrospektivno je promatrano 149 pacijenata koji su u razdoblju od 1. siječnja 2023. do 1. siječnja 2024. obrađeni na OHBP-u Kliničkog bolničkog centra Zagreb radi pneumonije. Za pacijente sa statinima i pacijente bez statina u terapiji, definirani su pokazatelji težine bolesti (hipoksemija, tahikardija, febrilitet, hipotenzija, ARI, dezorjentiranost pri pregledu, hiperglikemija, hiponatremija, PSI, CURB-65, potreba za hospitalizacijom, trajanje hospitalizacije, povratak u hitnu zbog povezanog razloga te ishode).
Pronađena je korelacija između terapije statinima i navedenih pokazatelja težine bolesti. PSI ljestvica, prisutnost tahikardije, hipotenzije, ARI, potreba za oksigenoterapijom i postotak hospitaliziranih pacijenata ukazivali su na blaži tijek bolesti u pacijenata na terapiji statinima, dok je prisutstvo dezorijentiranosti i ishod bolesti bio podjednak u obje skupine pacijenata.
Rezultati su u skladu s rezultatima drugih studija koje su proučavale učinak statina na druge upalne bolesti.
Buduće prospektivne studije s većim brojem pacijenata i jasno definiranim ishodima bolesti upotpuniti će rezultate ovog istraživanja i jasnije definirati potencijalnu praktičnu primjenu dokazanog. |
| Sažetak (engleski) | Medications from the statin group lower blood cholesterol levels by inhibiting the enzyme HMG-CoA reductase. Over years of widespread use, additional pleiotropic effects of statins have been discovered. Statins have been shown to possess anti-inflammatory, antioxidant, anti-aggregatory, and antiproliferative properties. The main aim of this research was to determine the impact of these properties on the course and outcome of pneumonia.
In this retrospective study, 149 patients who were treated at the Emergency Department of the Clinical Hospital Center Zagreb for pneumonia between January 1, 2023, and January 1, 2024, were observed. Indicators of disease severity (hypoxemia, tachycardia, fever, hypotension, ARI, disorientation during examination, hyperglycemia, hyponatremia, PSI, CURB-65, need for hospitalization, length of hospital stay, return to the emergency department for a related reason, and outcomes) were defined for patients on statin therapy and those without statins in their treatment.
A correlation was found between statin therapy and the aforementioned indicators of disease severity. The PSI scale, presence of tachycardia, hypotension, ARI, need for oxygen therapy, and the percentage of hospitalized patients indicated a milder course of disease in patients on statin therapy, while the presence of disorientation and the outcome of the disease were similar in both patient groups.
The results are consistent with those of other studies that have examined the effects of statins on other inflammatory diseases.
Future prospective studies with a larger number of patients and clearly defined disease outcomes will complement the results of this research and more clearly define the potential practical application of the findings. |
